CytomX Therapeutics (NASDAQ:CTMX) Given New $15.00 Price Target at Guggenheim

CytomX Therapeutics (NASDAQ:CTMX) had its price objective increased by Guggenheim from $10.00 to $15.00 in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other analysts also recently weighed in on CTMX. Wedbush lifted their target price on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a report on Tuesday. Oppenheimer restated an “outperform” rating and set a $12.00 price target on shares of CytomX Therapeutics in a research report on Monday. Cantor Fitzgerald boosted their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $7.00 to $12.00 in a research note on Monday. Finally, Piper Sandler raised their target price on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.56.

CytomX Therapeutics Trading Down 19.3%

Shares of NASDAQ:CTMX opened at $4.40 on Wednesday. The business has a 50-day moving average price of $5.27 and a 200 day moving average price of $4.10. The company has a market capitalization of $748.84 million, a price-to-earnings ratio of -110.00 and a beta of 2.44. CytomX Therapeutics has a 12-month low of $0.40 and a 12-month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. The company had revenue of $0.66 million during the quarter, compared to analyst estimates of $7.33 million. As a group, equities research analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC acquired a new position in shares of CytomX Therapeutics during the third quarter worth about $25,000. Wells Fargo & Company MN lifted its stake in CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,000 shares during the last quarter. Invesco Ltd. purchased a new position in CytomX Therapeutics in the second quarter worth approximately $32,000. Pursue Wealth Partners LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in CytomX Therapeutics during the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

Key Headlines Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple analysts raised price targets or upgraded the stock — Guggenheim raised its target to $15 and put a Buy on CTMX, Wedbush raised its target to $11 with an Outperform, and JPMorgan issued an upgrade — these notes signal continued institutional interest and provide upside conviction for the shares. Benzinga JPMorgan Upgrade
• Positive Sentiment: Clinical catalyst: strong Phase I Varseta‑M data in metastatic colorectal cancer previously triggered a rally and underpins investor optimism about the pipeline’s upside. Zacks
• Neutral Sentiment: Company posted its Q4 results presentation (useful for diligence), providing the latest formal disclosures on operations and pipeline progress. Investors should review the deck for cash runway details and program timelines. Q4 Presentation
• Negative Sentiment: Dilutive equity financing: CytomX priced a $250M offering at $5.30/share (≈46M shares plus pre‑funded warrants). The sale increases share count materially and is the primary near‑term headwind pressuring the stock. Offering Filing
• Negative Sentiment: HC Wainwright lowered near‑term EPS forecasts substantially (Q1–Q4 2026 and FY2026 cuts) even while maintaining a Buy and a $17 target; the reduced estimates highlight expected near‑term cash burn and push downside to short‑term earnings expectations. Analyst Note
• Negative Sentiment: Recent quarter missed consensus on EPS and revenue (reported March 16), underscoring why the company sought additional capital and why near‑term profitability looks distant. Earnings Coverage

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.